Urologic Diseases
122
22
26
53
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
13 trials with published results (11%)
Research Maturity
53 completed trials (43% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.2%
10 terminated out of 122 trials
84.1%
-2.4% vs benchmark
11%
13 trials in Phase 3/4
25%
13 of 53 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 53 completed trials
Clinical Trials (122)
Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora
Evaluation Patient Satisfaction After Passive Bladder Catheter Removal Compared to Active Removal
INTIBIA Pivotal Study
Effect of Comprehensive Spa Care on Kidney and Urological Conditions: A Clinical Study in Adult Patients
A Study of Ward Admissions for Haematuria
Registry for Patients Undergoing AUS Surgery for Female SUI Due to ISD
Active Informed Consent: a New Solution to Improve and Objectively Test the Patient Understanding of Complex Surgical Procedures Proposals
Evaluation of AI Large Models for Diagnosis and Treatment in Real-World Cases: Multicenter Retrospective Study
Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
VIrtual Reality Induced Pain and anxiEty Relief in Outpatient UROlogical Procedures
Bovine Colostrum for Prophylaxis Against Recurrent Urinary Tract Infection in Children
Modern Urodynamics System Efficacy (MUSE) Study
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
Trial for Reliability of Urodynamics SysTem
Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures
PACT Programme for Parents of Children With SHCN
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Long Term Extension Study in Patients With Primary Hyperoxaluria